Zoll Medical said yesterday it launched the ResQCPR system, which combines its ResQPump ACD-CPR and ResQPod impedance threshhold devices to aid individuals suffering from sudden cardiac arrest.
The combined devices are used together during CPR to create a vaccuum in the chest to improve blood flow to the brain and vital organs during states of low blood flow, the Chelmsford, Mass.-based company said.
“The ResQCPR System provides intrathoracic pressure regulation (IPR) therapy, which non-invasively improves circulation to vital organs without the use of pharmaceutical or other agents during CPR by enhancing the negative pressure or vacuum in the chest. If implemented widely in the United States, the ResQCPR System could save thousands of additional lives from cardiac arrest every year,” chief medical officer Dr. Keith Lurie said in prepared remarks.
In a clinical trial, the device was shown to improve survival to 1 year from out-of-hospital non-traumatic cardiac arrest by 49% compared to conventional CPR, the company said.
“We’ve only had the ResQCPR System in the field for 8 weeks, and we’re already seeing an impact on survival. Our initial experience with the devices has been very positive. Our paramedics and EMTs in Memphis County say it’s very intuitive, lightweight, and portable,” Dr. Joe Holley of Memphis EMS said in a press release.
In September, Zoll Medical was revealed as the mystery suitor behind a 35 million bid for Kyma Medical Technologies, a developer of remote cardiac monitoring devices, according to a regulatory filing by Elron Electronic Industries (TASE:ELRN), which owns a stake in Kyma.
Elron 1st announced the deal last June but did not name the potential acquirer. The deal includes potential earnouts worth an unspecified amount, according to thef iling, plus a 4½-year earnout schedule for an unspecified series of revenue-based milestones and sales royalties for 5½ years.